Overview

* Curis ( CRIS ) Q2 revenue rises to $2.7 mln, beating analyst expectations

* Net loss for Q2 narrows to $8.6 mln, exceeding analyst estimates

* Adjusted EPS for Q2 beats expectations, reflecting improved financial performance

Outlook

* Curis ( CRIS ) expects to begin enrollment for CLL study later this year

* Company plans head-to-head trial against gilteritinib in AML

* Curis ( CRIS ) anticipates data from AML triplet study in December

* Company's cash runway extended into Q1 2026

Result Drivers

* CLINICAL TRIAL PROGRESS - Curis ( CRIS ) cites ongoing enrollment in TakeAim Lymphoma study

* EXPENSE REDUCTION - Lower research and development costs contributed to improved financial results

* REVENUE INCREASE - Slight rise in royalty revenues from Genentech/Roche sales of Erivedge

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $2.75 $2.64

Revenue mln mln (5

Analysts

)

Q2 Net Beat -$8.59 -$14.30

Income mln mln (5

Analysts

)

Q2 Basic Beat -$0.68 -$0.89

EPS (4

Analysts

)

Q2 Beat -$8.25 -$14.20

Income mln mln (5

From Analysts

Operatio )

ns

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)